Annexin A2 as a novel diagnostic marker for serous ovarian cancer

Description:

Technology Background:

We have recently shown that annexin A2 is highly expressed in 90% of serous ovarian cancers, which is the most common subtype and is actively involved in the process of ovarian cancer metastasis. Moreover, we have also shown that local upregulation of annexin A2 within the tumour is reflected in a systemic ~2.0-fold increase of annexin A2 in the plasma of patients with early stage serous ovarian cancer. Ninety percent of patients with early stage disease had plasma annexin A2 levels greater than 300ng/ml whilst the non-cancer controls all had levels less than 300ng/ml. We plan to measure annexin A2 in combination with other markers including CA125 and HE4 , as a panel of blood biomarkers is very likely to increase the specificity and sensitivity to detect ovarian cancer.

Potential Product:

A quantitative multiplex Luminex assay for measuring ovarian cancer biomarkers in human plasma. Our target market for this diagnostic are all women of 50 years and above, as risk significantly increases for this age group and early stage ovarian cancer is generally asymptomatic. We envision that the test would be provided as a routine test for all women on a regular basis, similar to the current pap smear test used to diagnose cervical cancer. Ovarian cancer patients which are diagnosed at early stage would have a better survival rate and prognosis compared to advanced disease patients. There is currently no diagnostic on the market for early-stage ovarian cancer. An early diagnostic in this area will be a blockbuster product, with the potential to capture a major share of the market.

Intellectual property protection:

In November 2014 ARI filed a provisional patent application "Plasma Biomarker for ovarian cancer" to protect this technology.

Partnering Opportunities:

Currently, we are seeking partners for the continued development of this technology and/or prospective licensees.

Patent Information:
For Information, Contact:
Kiara Bechta-Metti
The University of Adelaide
Kiara.Bechta-Metti@adelaide.edu.au
Inventors:
Carmela Ricciardelli
Martin OEHLER
Keywords:
Biopharmaceuticals
Cancer
Diagnostics
Oncology
Reproductive